Yahoo
NYSE - Delayed Quote USD

Labcorp Holdings Inc. (LH)

360.25 +29.08 (+8.78%)
At close: October 28 at 4:00:02 PM EDT
366.00 +5.75 (+1.60%)
Pre-Market: 4:44:22 AM EDT
Trade LH on Coinbase
LH Q3 2026 earnings call
Replay the call for the latest insights.
Chart Range Bar
Loading chart for LH

What's happening with LH?

19m ago
Powered by Yahoo Scout

Labcorp delivered a broad Q3 beat, with 6.9% revenue growth, 14.5% adjusted EPS growth, and stronger margins. Management raised 2026 revenue and earnings guidance, while acquisitions and specialty-testing launches expanded growth prospects. The main offset is proposed 2027 Medicare reimbursement pressure of approximately $125 million.

Powered by Yahoo Scout
  • Previous Close 331.17
  • Open 344.55
  • Bid --
  • Ask --
  • Day's Range 341.40 - 371.00
  • 52 Week Range 244.52 - 371.00
  • Volume 1,797,123
  • Avg. Volume 727,395
  • Market Cap (intraday) 29.216B
  • Beta (5Y Monthly) 0.85
  • PE Ratio (TTM) 29.53
  • EPS (TTM) 12.20
  • Earnings Date Oct 28, 2026
  • Forward Dividend & Yield 2.88 (0.87%)
  • 1y Target Est 354.50
  • Morningstar Rating Rating available with Stock Picks access

Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics. The company was founded in 1995 and is headquartered in Burlington, North Carolina.

www.labcorp.com

71,000

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/28/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

LH
44.66%
S&P 500 (^GSPC)
13.13%

1-Year Return

LH
40.13%
S&P 500 (^GSPC)
12.38%

3-Year Return

LH
87.50%
S&P 500 (^GSPC)
88.08%

5-Year Return

LH
55.04%
S&P 500 (^GSPC)
68.48%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 3.81B
Earnings 262.8M
Profit Margin 6.90%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
1B
2B
3B
5.0%
6.0%
7.0%
8.0%

Analyst Insights

View More

Analyst Price Targets

293.00 Low
354.50 Average
360.25 Current
410.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 9/21/2026
Analyst Truist Securities
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 350 -> 365

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    6.99%

  • Return on Assets (ttm)

    5.53%

  • Return on Equity (ttm)

    11.73%

  • Revenue (ttm)

    14.35B

  • Net Income Avi to Common (ttm)

    1B

  • Diluted EPS (ttm)

    12.20

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    141.8M

  • Total Debt/Equity (mrq)

    79.12%

  • Levered Free Cash Flow (ttm)

    892.05M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: